Target intelligence / Profile preview

Rabies Virus Glycoprotein (RABV-G)

Target: RABV-G
Molecular classification: Type I transmembrane glycoprotein

Overview

The rabies virus glycoprotein (RABV-G) is the sole surface protein of the rabies virion and plays a central role in viral entry, pathogenesis, and immune recognition. It mediates attachment to host cell receptors, induces endocytosis of the virion, and triggers membrane fusion. It is the major target for neutralizing antibodies and essential for induction of protective immunity against rabies infection.

Mechanism of action

Neutralization of viral entry

Biological functions

Host cell attachmentInduction of endocytosisMembrane fusionImmune response induction

Disease associations

Infection

Safety considerations

Eliciting neutralizing antibodies

Beyond the preview

Go deeper on Rabies Virus Glycoprotein (RABV-G).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rabies Virus Glycoprotein (RABV-G).

Explore the full profile